Pub Date : 2022-12-01DOI: 10.1007/s12170-022-00709-8
Julio C Nunes, Shayena Shah, M. Fazal, Sofia E. Gomez, Chen Wei, Paul J. Wang, R. Stafford, T. Baykaner
{"title":"Patient Education Strategies to Improve Risk of Stroke in Patients with Atrial Fibrillation","authors":"Julio C Nunes, Shayena Shah, M. Fazal, Sofia E. Gomez, Chen Wei, Paul J. Wang, R. Stafford, T. Baykaner","doi":"10.1007/s12170-022-00709-8","DOIUrl":"https://doi.org/10.1007/s12170-022-00709-8","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48227467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-07DOI: 10.1007/s12170-022-00710-1
Bianca Cherestal, Z. Hudson, Keila N. Lopez
{"title":"Applying Interventions to Address the Social Determinants of Health and Reduce Health Disparities in Congenital Heart Disease Patients","authors":"Bianca Cherestal, Z. Hudson, Keila N. Lopez","doi":"10.1007/s12170-022-00710-1","DOIUrl":"https://doi.org/10.1007/s12170-022-00710-1","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41927887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-03DOI: 10.1007/s12170-022-00708-9
Cheryl L. Woods-Giscombe, Jamie Conklin, Adam Dodd, Louise F. Barthold, Yvonne Perry, J. Brooks, Andrew Bradford, Sierra Vines, Raven Smith, E. Ikharo, Erum Agha, Aisha Chilcoat, Karen Sheffield-Abdullah, S. Gaylord
{"title":"Workplace Meditation Interventions for Reducing Psychological Stress and Other Cardiovascular Risk Factors: Workplace Wellness Policy Implications","authors":"Cheryl L. Woods-Giscombe, Jamie Conklin, Adam Dodd, Louise F. Barthold, Yvonne Perry, J. Brooks, Andrew Bradford, Sierra Vines, Raven Smith, E. Ikharo, Erum Agha, Aisha Chilcoat, Karen Sheffield-Abdullah, S. Gaylord","doi":"10.1007/s12170-022-00708-9","DOIUrl":"https://doi.org/10.1007/s12170-022-00708-9","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43734631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-24DOI: 10.1007/s12170-022-00705-y
G. Wilkie, Ekaterina Skaritanov, Micaela Tobin, Angela Essa, A. Gubala, L. Ferraro, Lara C Kovell
{"title":"Hypertension in Women: Impact of Contraception, Fertility, and Hormone Treatment","authors":"G. Wilkie, Ekaterina Skaritanov, Micaela Tobin, Angela Essa, A. Gubala, L. Ferraro, Lara C Kovell","doi":"10.1007/s12170-022-00705-y","DOIUrl":"https://doi.org/10.1007/s12170-022-00705-y","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48915527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-06DOI: 10.1007/s12170-022-00707-w
K. Tamirisa, C. Dye, I. Ekeruo, A. Volgman
{"title":"Atrial Fibrillation in Women: from Epidemiology to Treatment","authors":"K. Tamirisa, C. Dye, I. Ekeruo, A. Volgman","doi":"10.1007/s12170-022-00707-w","DOIUrl":"https://doi.org/10.1007/s12170-022-00707-w","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41801256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-01Epub Date: 2022-06-25DOI: 10.1007/s12170-022-00694-y
Sean Paul Gaine, Renato Quispe, Jaideep Patel, Erin D Michos
Purpose of review: The primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) relies on optimizing cardiovascular health and appropriate pharmacotherapy, a mainstay of which is low-density lipoprotein-cholesterol (LDL-C) lowering. Typically, statin therapy remains the first line approach. Advances in technology and understanding of lipid metabolism have facilitated the development of several novel therapeutic targets and medications within the last decade. This review focuses on medications recently approved by the U.S. Food and Drug Administration (FDA) for the reduction of LDL-C and ASCVD risk, as well as new therapies in the pipeline.
Recent findings: Novel lipid therapies aim to lower risk of ASCVD by targeting reduction of atherogenic compounds, such as LDL, lipoprotein(a) (Lp(a)), and triglyceride-rich lipoproteins. Evolocumab and alirocumab, monoclonal antibody proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors which lower LDL-C by approximately 60%, have emerged as important therapies for use in patients with ASCVD as well as familial hypercholesterolemia (FH). Bempedoic acid, an ATP citrate lyase inhibitor, is an oral medication recently approved that can lower LDL-C by approximately 18% alone and 38% when combined with ezetimibe. Inclisiran, a small-interfering RNA (siRNA) molecule which inhibits the translation of PCSK9, is the most recently FDA-approved LDL-C lowering medication, and can reduce LDL-C by approximately 50% with twice yearly subcutaneous dosing. The cardiovascular outcome trials for bempedoic acid and inclisiran are still on-going. Evinacumab, a monoclonal antibody which targets angiopoietin-like protein 3 (ANGPTL3), has been approved for use in patients with homozygous FH. SiRNAs and anti-sense oligonucleotides (ASO) facilitating selective inhibition of the production of targeted proteins including Lp(a) and ANGLPTL3 are active areas of clinical investigation.
Summary: Recently several novel LDL-C lowering medications have been approved. New therapeutic targets have been identified and present additional means of lowering LDL-C and other atherogenic compounds for patients who remain at high ASCVD risk.
{"title":"New Strategies for Lowering Low Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention.","authors":"Sean Paul Gaine, Renato Quispe, Jaideep Patel, Erin D Michos","doi":"10.1007/s12170-022-00694-y","DOIUrl":"10.1007/s12170-022-00694-y","url":null,"abstract":"<p><strong>Purpose of review: </strong>The primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) relies on optimizing cardiovascular health and appropriate pharmacotherapy, a mainstay of which is low-density lipoprotein-cholesterol (LDL-C) lowering. Typically, statin therapy remains the first line approach. Advances in technology and understanding of lipid metabolism have facilitated the development of several novel therapeutic targets and medications within the last decade. This review focuses on medications recently approved by the U.S. Food and Drug Administration (FDA) for the reduction of LDL-C and ASCVD risk, as well as new therapies in the pipeline.</p><p><strong>Recent findings: </strong>Novel lipid therapies aim to lower risk of ASCVD by targeting reduction of atherogenic compounds, such as LDL, lipoprotein(a) (Lp(a)), and triglyceride-rich lipoproteins. Evolocumab and alirocumab, monoclonal antibody proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors which lower LDL-C by approximately 60%, have emerged as important therapies for use in patients with ASCVD as well as familial hypercholesterolemia (FH). Bempedoic acid, an ATP citrate lyase inhibitor, is an oral medication recently approved that can lower LDL-C by approximately 18% alone and 38% when combined with ezetimibe. Inclisiran, a small-interfering RNA (siRNA) molecule which inhibits the translation of PCSK9, is the most recently FDA-approved LDL-C lowering medication, and can reduce LDL-C by approximately 50% with twice yearly subcutaneous dosing. The cardiovascular outcome trials for bempedoic acid and inclisiran are still on-going. Evinacumab, a monoclonal antibody which targets angiopoietin-like protein 3 (ANGPTL3), has been approved for use in patients with homozygous FH. SiRNAs and anti-sense oligonucleotides (ASO) facilitating selective inhibition of the production of targeted proteins including Lp(a) and ANGLPTL3 are active areas of clinical investigation.</p><p><strong>Summary: </strong>Recently several novel LDL-C lowering medications have been approved. New therapeutic targets have been identified and present additional means of lowering LDL-C and other atherogenic compounds for patients who remain at high ASCVD risk.</p>","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543364/pdf/nihms-1819176.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10133436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-23DOI: 10.1007/s12170-022-00703-0
R. Bond, Kameelah Phillips, Kendra N. Ivy, Vanessa Ogueri, B. Parapid, S. C. Miller, Annette K. Ansong
{"title":"Cardiovascular Health of Black Women Before, During, and After Pregnancy: A Call to Action and Implications for Prevention","authors":"R. Bond, Kameelah Phillips, Kendra N. Ivy, Vanessa Ogueri, B. Parapid, S. C. Miller, Annette K. Ansong","doi":"10.1007/s12170-022-00703-0","DOIUrl":"https://doi.org/10.1007/s12170-022-00703-0","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43019176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-23DOI: 10.1007/s12170-022-00701-2
D. Adedinsewo, Ivan E. Porter, R. White, L. Hickson
{"title":"Racial and Ethnic Disparities in Cardiovascular Disease Risk Among Patients with Chronic Kidney Disease","authors":"D. Adedinsewo, Ivan E. Porter, R. White, L. Hickson","doi":"10.1007/s12170-022-00701-2","DOIUrl":"https://doi.org/10.1007/s12170-022-00701-2","url":null,"abstract":"","PeriodicalId":46144,"journal":{"name":"Current Cardiovascular Risk Reports","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44491779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号